LIFCASUS Trademark

Trademark Overview


On Thursday, February 20, 2020, a trademark application was filed for LIFCASUS with the United States Patent and Trademark Office. The USPTO has given the LIFCASUS trademark a serial number of 88803877. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 11, 2024. This trademark is owned by Celgene Corporation. The LIFCASUS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, including T Cell therapy; P...
lifcasus

General Information


Serial Number88803877
Word MarkLIFCASUS
Filing DateThursday, February 20, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 11, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 15, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, including T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 25, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events


Event DateEvent Description
Monday, March 11, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 11, 2024ABANDONMENT - NO USE STATEMENT FILED
Friday, August 11, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 10, 2023SOU EXTENSION 5 GRANTED
Wednesday, August 2, 2023SOU EXTENSION 5 FILED
Thursday, August 10, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 2, 2023SOU TEAS EXTENSION RECEIVED
Friday, February 3, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 1, 2023SOU EXTENSION 4 GRANTED
Wednesday, February 1, 2023SOU EXTENSION 4 FILED
Wednesday, February 1, 2023SOU TEAS EXTENSION RECEIVED
Friday, July 29, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 27, 2022SOU EXTENSION 3 GRANTED
Wednesday, July 27, 2022SOU EXTENSION 3 FILED
Wednesday, July 27, 2022SOU TEAS EXTENSION RECEIVED
Thursday, February 10, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 8, 2022SOU EXTENSION 2 GRANTED
Tuesday, February 8, 2022SOU EXTENSION 2 FILED
Tuesday, February 8, 2022SOU TEAS EXTENSION RECEIVED
Saturday, August 7, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 5, 2021SOU EXTENSION 1 GRANTED
Thursday, August 5, 2021SOU EXTENSION 1 FILED
Thursday, August 5, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, February 9, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 15, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 15, 2020PUBLISHED FOR OPPOSITION
Wednesday, November 25, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, November 12, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, November 6, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, November 5, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 5, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, May 8, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, May 8, 2020NON-FINAL ACTION E-MAILED
Friday, May 8, 2020NON-FINAL ACTION WRITTEN
Friday, May 8, 2020ASSIGNED TO EXAMINER
Tuesday, February 25, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, February 24, 2020NEW APPLICATION ENTERED